Januvia vs Tradjenta

Januvia
Tradjenta
Satisfaction Score
?
2.7
Slightly Satisfied
Satisfaction Score
?
2.5
Slightly Satisfied
Helpfulness
for Diabetes
2.9
Concern level
3.6
Helpfulness
for Diabetes
3.9
Concern level
3.5
11,844
Discussions around the web
Discussions
858
Discussions around the web
Discussions
Taken for:
by discussions around the web
Diabetes
Type 2 Diabetes
Taken for:
by discussions around the web
Diabetes
Type 2 Diabetes
Method of use:
Pill
Method of use:
Pill
Prescribing mode:
Rx
Prescribing mode:
Rx
Sitagliptin (International Nonproprietary Name previously identified as MK-0431 and marketed as sitagliptin phosphate under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the DPP-4 inhibitors class. It was devel...
Read on Wikipedia
Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of Diabe...
Read on Wikipedia
Top Concerns
Jan
Weight Loss
10
Weight Gain
8
Hypoglycemia
7
Nausea
4
Insulin Resistance
3
Hyperglycemia
3
Headaches
3
Pancreatitis
3
Tiredness
2
Diarrhea
2
Top Concerns
Tra
Hypoglycemia
7
Weight Gain
6
Weight Loss
5
Dizziness
4
Hyperglycemia
4
Pancreatitis
4
Headaches
3
Allergy
3
Kidney Failure
3
Kidney Disease
3
Compare concerns
By:
Januvia
Jan
Tradjenta
Tra
Weight Loss
Jan
Tra
10
5
Weight Gain
Jan
Tra
8
6
Hypoglycemia
Jan
Tra
7
7
Nausea
Jan
Tra
4
0
Insulin Resistance
Jan
Tra
3
0
Hyperglycemia
Jan
Tra
3
4
Headaches
Jan
Tra
3
3
Pancreatitis
Jan
Tra
3
4
Tiredness
Jan
Tra
2
0
Diarrhea
Jan
Tra
2
0
Hypoglycemia
Tra
Jan
7
7
Weight Gain
Tra
Jan
6
8
Weight Loss
Tra
Jan
5
10
Dizziness
Tra
Jan
4
0
Hyperglycemia
Tra
Jan
4
3
Pancreatitis
Tra
Jan
4
3
Headaches
Tra
Jan
3
3
Allergy
Tra
Jan
3
0
Kidney Failure
Tra
Jan
3
0
Kidney Disease
Tra
Jan
3
0
Back
About Januvia
Sitagliptin (International Nonproprietary Name previously identified as MK-0431 and marketed as sitagliptin phosphate under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the DPP-4 inhibitors class. It was devel...
Read on Wikipedia
Read more about:
Januvia
About Tradjenta
Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of Diabe...
Read on Wikipedia
Read more about:
Tradjenta
content loaded dynamically
Filter by
Filter by
Gender
Role
Age
All
We found 94 discussions
Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general. Treato does not provide medical advice, diagnosis or treatment. Usage of the website does not substitute professional medical advice.
The side effects featured here are based on those most frequently appearing in user posts on the Internet. The manufacturer's product labeling should always be consulted for a list of side effects most frequently appearing in patients during clinical studies. Talk to your doctor about which medications may be most appropriate for you.
The information reflected here is dependent upon the correct functioning of our algorithm. From time-to-time, our system might experience bugs or glitches that affect the accuracy or correct application of mathematical algorithms. We will do our best to update the site if we are made aware of any malfunctioning or misapplication of these algorithms. We cannot guarantee results and occasional interruptions in updating may occur. Please continue to check the site for updated information.
Treato does not provide medical advice, diagnoses or treatment. Services are ranked based on reviews gathered from around the web and may refer to different aspects of each service (Price, waiting time, general satisfaction, etc.) Treato does not guarantee any specific rate or promotion. In addition, prices for some services provided by the listed Telehealth companies may vary, please check with the Telehealth site for the exact price for the desired service. Treato is not responsible for promotions validity, application of the promotion code varies among the different Telehealth sites (for example during registration flow). It is your responsibility to apply the promotion code. Treato is not responsible for content on external web sites.
Welcome back! Sign in
See what other patients are saying
First time here? Sign up!
See what other patients are saying
Forgot your password?
No problem, we can help.
Back to Signup
Please wait...